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pulmonary disease at intensive care unit admission
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Background: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are thought to be
associated with increased mortality in elderly patients. Low retinol-binding protein-4 (RBP4) is associated with a
high risk of respiratory infections in the general population. Therefore, we hypothesized that low RBP4 levels are
associated with an increased risk of AECOPD and can be used as a biomarker for AECOPD in elderly patients.
Methods: Enzyme-linked immunosorbent assays were used to assess RBP4 levels in elderly with AECOPD within the
first 24 hours after intensive care unit admission. Forty-six elderly patients with stable COPD in outpatient clinics
and 50 healthy elderly persons who had physical examinations as outpatients were controls.
Results: In AECOPD patients, RBP4 levels were lower than those in stable COPD patients and healthy controls
(59.7 vs 91.2 and 113.6 mg/L, p < 0.001). RBP4 levels were decreased by 30.6% in non-survivors compared with
survivors (51.5 vs 74.2 mg/L, p < 0.001). A higher Acute Physiology and Chronic Health Enquiry II (APACHE II)
score and Simplified Acute Physiology score (SAPS II) were associated with lower RBP4 levels (r = −0.692, p = 0.024
and r = −0.670, p = 0.015, respectively). RBP4 was positively correlated with creatinine and body mass index, and
negatively correlated with C-reactive protein and Global Initiative for Chronic Obstructive Lung Disease stage.
Multivariate logistic regression showed that RBP4 was an independent mortality predictor of AECOPD (odds ratio:
0.926, p = 0.007). Analysis of the area under the receiver operating characteristic (AUC) curve showed that RBP4
showed good discrimination (AUC: 0.88; 95% confidence interval: 0.78–0.94; p = 0.008) in predicting mortality.
RBP4 improved the prognostic accuracy of mortality for the APACHE II and SAPS II scores.
Conclusions: Serum RBP4 levels are significantly reduced in elderly AECOPD patients. RBP4 might be a good
predictive biomarker for mortality in elderly AECOPD patients in the intensive care unit.
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Chronic obstructive pulmonary disease (COPD) is a
condition characterized by progressive airflow limitation,
which causes considerable morbidity and mortality
worldwide, and results in substantial social and economic
burden [1]. Patients with acute exacerbations of chronic
obstructive pulmonary disease (AECOPD), particularly
elderly people, have high mortality rates and usually need
admission to intensive care units (ICUs) [2]. Mortality
rates of aged patients with AECOPD in ICU can be up to
50% [3]. The risk of 90-day mortality is three times as
great in elderly patients admitted with AECOPD as in
younger patients [4]. Many factors have been identified as
predictors of ICU mortality in patients with COPD [5],
but the predictive value of the clinical parameters varies in
different studies.
Recently, considerable attention has been paid to
adipocytokines, biologically active factors secreted by
adipose tissue as an endocrine organ [6]. Several hormones
secreted by adipose tissue have been identified to be
involved in acute critical illness [7]. Adipose tissue is
an important inflammatory source because of cytokines
produced from the adipocyte itself, as well as owing to
infiltration by proinflammatory macrophages [8]. Adipose
tissue is a potent producer of inflammatory mediators and
may contribute to systemic inflammation in COPD [9].
Adipokines are associated with the systemic inflammatory
process during exacerbations of COPD [10].
Retinol-binding protein-4 (RBP4) is a molecule found in
the circulation, thought to be secreted mainly by adipose
tissue and the liver, and is a specific transporter for retinol
in the circulation [11]. RBP4 has been identified as an
adipokine involved in detection of insulin resistance and
type 2 diabetes [12]. Recently, RBP4 has been extensively
studied and is associated with various pathologies [13,14].
However, no studies have investigated the relationship
between RBP4 and AECOPD.
This study aimed to identify whether RBP4 is predictive
for mortality among various risk factors in elderly AECOPD
patients in the ICU. We report here that lower levels of
plasma RBP4 have a higher risk of mortality and can be




COPD was defined as dyspnea, chronic cough, or sputum
production and/or a history of exposure to risk factors
for the disease, and post-bronchodilator 1-second forced
expiratory volume/forced vital capacity (FEV1/FVC) < 70%
according to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines [15]. Pulmonary function
testing was performed in a hospital pulmonary function
laboratory by trained technicians according to AmericanThoracic Society and European Respiratory Society standards
and guidelines [16]. Mild, moderate, and severe COPD
were defined based on GOLD guidelines as follows.
Mild COPD was defined as an FEV1/FVC ratio < 0.7 and
FEV1 % ≥80% predicted. Moderate COPD was defined as
an FEV1/FVC ratio < 0.7 and FEV1 % 50–79% predicted.
Severe COPD was defined as an FEV1/FVC ratio < 0.7 and
FEV1 % 30–49% predicted. Very severe COPD was defined
as an FEV1/FVC ratio < 0.7 and FEV1 % < 30% predicted.
Patients with AECOPD admitted to the ICU must meet
at least one of the following indications [17]: (1) severe
dyspnea that responds inadequately to initial emergency
therapy; (2) changes in mental status (confusion, lethargy,
coma); (3) persistent or worsening hypoxemia (PaO2 < 5.3
kPa, 40 mmHg), and/or severe/worsening of hypercapnia
(PaCO2 > 8.0 kPa, 60 mmHg), and/or severe/worsening
of respiratory acidosis (pH < 7.25) despite supplemental
oxygen and noninvasive ventilation; (4) the need for
invasive mechanical ventilation; (5) hemodynamic in-
stability and the requirement for vasopressors. Exclusion
criteria included interstitial pneumonia, asthma, pulmonary
tuberculosis, bronchiectasis, pulmonary fibrosis, and
lung cancer according to clinical history and data [18].
Arterial blood gas analysis was completed immediately
at ICU admission.
Systemic inflammatory response syndrome (SIRS) accord-
ing to international, standardized criteria [19] was charac-
terized by the presence of at least two of the following
four clinical criteria: (1) fever or hypothermia (temperature >
38.0°C or < 36.0°C); (2) tachycardia (> 90 beats/min); (3)
tachypnoea > 20 breaths/min or < 32 mmHg, or the need
for mechanical ventilation support; (4) altered white blood
cell (WBC) count (> 12 000 cells/μl or < 4000 cells/μl) or
the presence of > 10% band forms. Sepsis was defined as
SIRS with an infection based on the 1991 American College
of Chest Physicians/Society of Critical Care Medicine Sepsis
Directory [20].
According to the above criteria, a total of 100 patients
admitted to the First and Sir Run Run Shaw Hospitals
from September 2010 to February 2012 were recruited.
Clinical data within the first 24 hours after ICU admission
were collected. All patients were aged ≥65 years, with
an ICU stay of ≥72 hours. All patients were scheduled
for a follow-up visit until being discharged from the
ICU (survivors) or they died in the ICU (non-survivors).
To further analyze the prognostic role of RBP4 for
AECOPD, we subdivided the patients according to
whether they had type 2 diabetes mellitus (T2DM) or
sepsis. T2DM was diagnosed according to American
Diabetes Association criteria [21], and sepsis was defined
during first 24 hours at the ICU admission.
Forty-six stable (no exacerbations for at least 4 weeks
prior to study entry) [18] COPD patients who had normal
blood counts, liver enzymes, and C-reactive protein (CRP)
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COPD healthy elderly people determined by physical
examination as outpatients served as controls.
Written informed consent was obtained from each
participant or his or her spouse, and the study was
approved by the local ethics committee (ethics committee
of the First and Sir Run Run Shaw Hospitals, Zhejiang
University, Zhejiang, China).
Sample and data collection
Routine blood analyses, including WBC, total bilirubin
(TB), γ-glutamyl transferase, albumin (ALB), blood urea
nitrogen, serum creatinine (sCr), lactic acid (LA), CRP,
B-type natriuretic peptide (BNP), procalcitonin (PCT),
RBP4, and blood and sputum culture were immediately
performed after admission to the ICU. RBP4 serum
concentrations were measured by enzyme-linked im-
munosorbent assay according to the manufacturer’s
instructions (Shanghai Resun Biotechnology Limited
Company, Shanghai, China). BNP was measured by the
electrochemiluminescence technique (cobas h 232 system,
Roche, Germany). PCT was measured by enzyme link
fluorescence assay (mini-VIDAS, automatic immune
fluorescence analyzer, France). The homeostasis model
assessment for insulin resistance (HOMA-IR) was used
as a measurement of insulin resistance and was calculated
as fasting plasma glucose (mmol/L) × fasting serum
insulin (mU/mL)/22.5. The Acute Physiology and Chronic
Health Evaluation (APACHE) II score, and Simplified
Acute Physiology Score (SAPS II) were evaluated within
the first 24 hours (day 1) after ICU admission.
Data analysis
For statistical analysis, measurements of RBP4, ALB, LA,
PCT, and CRP were logarithmically transformed to obtain
normal distributions (Kolmogorov-Smirnov test, p > 0.05).
Data are presented as mean and standard deviation, or
median and interquartile range, as appropriate. Fisher's
exact was used for comparison of the primary disease
between the non-survivor group and the survivor group.
For comparison of study variables between the two
groups, the Student’s t-test or Mann–Whitney U test
was performed. Pearson’s correlation coefficients were




Age median (range)(yr) 76 (66–91)
BMI median (range)(m2/kg) 20.7 (17.2-26.4) 2
RBP4 median(range)(mg/L) 59.7 (21.3-128.6) 91
BMI, body mass index; RBP4, retinol-binding protein-4. ns, not significant; *p < 0.01RBP4 levels and other clinical and metabolic variables.
We assessed the risk factors for ICU mortality using
univariate analysis and multiple logistic regression analysis
to determine independent factors and dependent factors
for prognosis.
We compared the number of risk factors for the death
probability of AECOPD. Discrimination was calculated
using area under the curve (AUC) values. The AUC
values were compared using a nonparametric approach.
AUC analysis was also used to calculate the cut-off
values, sensitivity, specificity, and overall correctness.
Finally, cut-off points were calculated by calculating the
best Youden index (sensitivity+specificity-1). Cumulative
survival curves as a function of time were plotted using
the Kaplan–Meier approach and were compared using the
log rank test. A p value < 0.05 was considered statistically
significant. All statistical analyses were performed using
SPSS 15.0 (SPSS, Chicago, IL).
Results
RBP4 serum levels are significantly reduced in AECOPD
patients compared with stable COPD patients and
healthy controls
The median serum concentration of RBP4 in stable COPD
was 91.2 mg/L and in healthy controls it was 113.6 mg/L.
AECOPD patients had significantly reduced serum RBP4
concentrations compared with stable COPD patients and
healthy controls (median, 59.7 vs. 91.2 and 113.6 mg/L,
p < 0.001; Table 1). AECOPD patients had a lower body
mass index (BMI) compared with stable COPD patients
and healthy controls (median, 20.7 vs. 21.6 and 23.4,
p < 0.01). Serum RBP4 levels were different between
male and female patients.
Descriptive characteristics of the patients
A total of 100 AECOPD patients meeting ICU admission
standards [22] were included in this study. The median
age was 76 years and 26% were females. In 54 patients
(54%), SIRS with evidence of underlying infection was
found. The principal diagnoses in these patients included
diabetes (n = 26), coronary heart disease (n = 57), hyperten-
sion (n = 58), cerebrovascular disease (n = 43), renal failure
(n = 21), and respiratory failure (n = 76). The median length
of stay in the medical ICU was 12 days. Risk assessment onD patients, and healthy controls
table COPD Healthy controls p value
46 50
34/12 34/16 ns
75 (65–89) 75 (65–86) ns
1.6* (17.8-27.5) 23.4** (19.5-26.8) < 0.01
.2* (42.1-343.9) 113.6** (57.2-369.2) < 0.001
, AECOPD vs stable COPD; **p < 0.001, stable COPD vs healthy controls.
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of 24 points and a median SAPS II score of 40. Spirometry
confirmed that all patients had moderate to very severe
COPD (GOLD II-IV). Mean FEV1 was 40% predicted
(range, 24–66%), and the mean FEV1/FVC ratio was 45%
(28–63%).
A total of 64 patients (48 males, 16 females) who died
were included in the non-survivor group and 36 patients
(26 males, 10 females) who survived were included in




Age median (yr) 76 (66–91)
Duration of COPD (mo) 201 (18–350)
Duration of AECOPD (d) 8 (1–17)
ICU days median (d) 12 (3–28)
FEV1 (%predicted) 40 (24–66)
FVC (% predicted) 71 (47–85)
FEV1/FVC ratio (%) 45 (28–63)
PH 7.37 (7.21-7.52)
PaO2 (mm Hg) 63 (54–88)
PaCO2 (mm Hg) 65 (38–88)
Severity of COPD
GOLD stage II (moderate), n (%) 14(14%)
GOLD stage III (severe), n (%) 60(60%)
GOLD stage IV (very severe), n (%) 26(26%)
APACHE-II score 24 (18–38)
SAPS II score 40 (22–62)
BMI (m2/kg) 20.7 (17.2-26.4)
Caloric intake (kcal/d) 1274 (922–1689)
SIRS, n (%) 71(71%)
Sepsis, n (%) 54(54%)
White blood cells (109/L) 12.3 (1.8-32.2)
BNP (pg/ml) 546 (176–1208)
Total bilirubin (μmol/L) 22.5 (4.2-55.7)
Serum albumin (g/L) 3.1 (2.2-4.4)
Serum creatinine (mg/dl) 1.3 (0.5–3.2)
Lactic acid (mmol/L) 2.2 (0.8-5.3)
C-reactive protein (mg/dl) 49 (15–229)
Procalcitonin (μg/L) 2.8 (0.5-15.7)
RBP-4 (mg/L) 59.7 (21.3-128.6)
ICU, intensive care unit; FEV1, 1-second forced expiratory volume; FVC, forced vital c
simplified acute physiology score; BMI, body mass index; SIRS, systemic inflammato
protein-4. Compared with Survivors, *p < 0.05, **p < 0.01.diseases (diabetes, coronary heart disease, hypertension,
cerebrovascular disease, and renal failure), ICU days,
pulmonary function, and blood gas analysis tests were
not significantly different between the two groups.
Premorbid diseases have not been shown to be predictive
of outcome. The durations of AECOPD, APACHE II and
SAPS II scores, mechanical ventilation, and ventilation
time were significantly elevated in the non-survivor
group compared with the survivor group (p < 0.05 or <
0.01, Table 2).th AECOPD to the ICU within the first 24 hours
Survivors Non-survivors p value
36 64
26/10 48/16 0.761
74 (66–88) 77 (66–91) 0.799
199 (18–328) 204 (22–350) 0.611
6 (1–16) 9* (2–17) 0.004
11 (3–28) 13 (5–28) 0.073
43 (28–66) 38 (24–64) 0.224
74 (49–85) 68 (47–81) 0.218
48 (30–63) 43 (28–60) 0.418
7.40 (7.21-7.49) 7.36 (7.21-7.52) 0.781
66 (57–88) 62 (54–84) 0.556
68 (42–84) 63 (38–88) 0.218
12(33.33%) 2(3.13%) < 0.001
20(55.56%) 40(62.5%) < 0.001
4(11.11%) 22(34.37%) < 0.001
22 (18–37) 25** (19–38) 0.001
38 (22–60) 42** (24–70) 0.001
20.9 (18.3-26.0) 20.6 (17.2-26.4) 0.072
1418 (1220–1689) 1100** (922–1425) 0.001
20(55.56%) 48(75%)* 0.045
12(33.33%) 42(65.63%)** 0.002
12.5 (2.0-30.6) 12.2 (1.8-32.2) 0.073
455 (176–1010) 557 (221–1208) 0.069
21.7 23.5* (5.4-55.7) 0.047
(4.2-43.4)
3.2 (2.6–4.4) 3.0 (2.2–3.8) 0.173
1.2 (0.6–3.1) 1.3 (0.5–3.2) 0.279
2.1 (0.8-4.7) 2.3* (0.8-5.3) 0.038
52 (34–203) 48 (15–229) 0.066
2.7 (0.5-12.4) 2.9 (1.7-15.7) 0.051
74.2 (32.6-128.6) 51.5** (21.3-84.2) 0.001
apacity; APACHE, acute physiology and chronic health evaluation; SAPS,
ry response syndrome; BNP, B-type natriuretic peptide; RBP4, Retinol-binding
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We investigated whether serum RBP4 concentrations upon
ICU admission can predict clinical outcome and mortality.
Interestingly, patients who died during ICU hospitalization
(64/100) displayed significantly lower serum RBP4
concentrations than patients who survived (mg/L; 51.5
[21.3–84.2] vs 74.2 [32.6–128.6], p < 0.001) (Figure 1a). In
survivors, differences were more pronounced in the
APACHE II score (p = 0.008), the SAPS II score (p = 0.005),
LA (p = 0.032), TB (p = 0.044), duration of AECOPD
(p = 0.037), and ventilation time (p = 0.001) compared
with non-survivors. By contrast, WBC (p = 0.06), CRP
(p = 0.08), PCT levels (p = 0.24), and FEV1 (p = 0.224)
were similar in the survivor and non-survivor groups.
In addition, BMI (p = 0.072), metabolic parameters on
admission, including glucose (p = 0.57), and ALB levels
(p = 0.33) were not different between survivors and
non-survivors (Table 2). Severe COPD (GOLD III–IV)
mortality rate was 72.1%. The higher the GOLD grade,
the higher the mortality rate, with the risk of mortality
related to the GOLD classification [23]. RBP4 levels were
negatively correlated with GOLD stage by Pearson’s
correlation (r = −0.34, p = 0.001).RBP4 levels in AECOPD patients with sepsis and those
without sepsis
AECOPD is frequently associated with SIRS, which evolves
into septic shock and has a high mortality. To investigate
the role of RBP4 levels in AECOPD with sepsis, patients
were classified into those with sepsis and those without
sepsis. We found that AECOPD patients with sepsis had
significantly lower RBP4 levels compared with patients
without sepsis (mg/L; 47.4 [21.9–82.4] vs 83.1 [23.3–
128.6], p = 0.008) (Figure 1b). In all patients, RBP4 levels
decreased with increased severity of the disease. High-risk
patients in the highest quartile of the APACHE II score
and in the highest quartile of the SAPS II score had signifi-
cantly lower RBP4 concentrations (r = −0.692, p = 0.024
and r = −0.670, p = 0.015) (Figure 2a, b).Figure 1 RBP4 levels in AECOPD patients among the different groups
with sepsis and those without sepsis. (c) RBP4 levels in patients with diabeRBP4 levels in AECOPD patients with diabetes and those
without diabetes
In our study, DM was not a crucial factor of prognosis
in AECOPD patients (Table 2). RBP4 levels were not
different between patients with and those without pre-
existing T2DM on admission to the ICU (mg/L; 72.2
[24.7–128.6] vs 68.6 [21.3–119.2], p = 0.774) (Figure 1c).
RBP4 concentrations in patients with diabetes were not
correlated with insulin sensitivity as calculated by the
HOMA-IR (r = 0.473, p = 0.218, Figure 2c).
Factors affecting RBP4 levels
RBP4 levels were not correlated with age in AECOPD
(r = −0.002, p = 0.988) (Figure 3a). RBP4 levels were
associated with liver, renal, and heart function. Liver
function was identified as a strong predictor of RBP4
because RBP4 levels were directly correlated with parame-
ters indicating the liver’s biosynthetic capacity, such as TB
(r = −0.252, p = 0.011) (Figure 3b). RBP4 levels were also
correlated with markers of renal failure, specifically sCr
(r = 0.224, p = 0.005) (Figure 3c), but they were not
correlated with BNP (r = −0.005, p = 0.958) (Figure 3d)
and ALB (r = 0.199, p = 0.057) levels (Figure 3e). BMI had
a significant effect on RBP4 levels in AECOPD patients
(r = 0.205, p = 0.043) (Figure 3f ). There was an inverse
correlation between RBP4 levels and CRP levels (r = −0.183,
p = 0.044) (Figure 3g), while no correlation between
RBP4 and PCT levels was found (r = −0.073, p = 0.472)
(Figure 3h).
RBP4 is a prognostic marker of mortality in
AECOPD patients
To assess the prediction of RBP4 on the prognosis of
mortality of AECOPD patients, we performed univariate
and multivariate logistic regression, which compared the
prognostic values of RBP4 and other well known risk
factors, including age, BMI, the APACHE II score, the
SAPS II score, glucose levels, TB levels, WBC, LA, CRP
levels, and PCT levels. As shown in Table 3, RBP4, LA,
TB, the APACHE II score, and the SAPS II score were. (a) RBP4 levels in survivors and non-survivors. (b) RBP4 in patients
tes and those without diabetes.
Figure 2 Correlations between RBP4 levels and the APACHE II score, the SAPS II score, and HOMA-IR. (a) Correlation between RBP4 levels
and the APACHE II score (r = −0.692, p = 0.024). (b) Correlation between RBP4 levels and the SAPS II score (r = −0.670, p = 0.015). (c) Correlation
between RBP4 levels and HOMA-IR (r = 0.218, p = 0.473).
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among discriminatory values of the nine risk factors is
also shown in Table 4. The discriminatory ability of
RBP4 with the AUC was 0.88 (95% confidence interval
[CI] [0.78–0.94)], p = 0.008), the APACHE II score with
the AUC was 0.75 (95% CI [0.66–0.84], p = 0.036), and
the SAPS II score with the AUC was 0.77 (95% CI
[0.67–0.86], p = 0.028). AUC analysis showed that
RBP4 has the best discriminatory power. A combined
model including RBP4 and the APACHE II score (AUC:
0.75 vs 0.78, p = 0.042) improved the prognostic accuracy
compared with the APACHE II score alone. Similarly,
RBP4 tended to improve the prognostic accuracy of the
SAPS II score in a combined model (AUC: 0.77 vs 0.81,
p = 0.033).Figure 3 Correlations between RBP4 levels and other risk factors. (a)
Correlation between RBP4 levels and TB (total bilirubin) (r = −0.252, p = 0.0
(d) Correlation between RBP4 levels and BNP (r = −0.005, p = 0.958). (e) Co
Correlation between RBP4 levels and BMI (r = 0.205, p = 0.043). (g) Correlat
Correlation between RBP4 levels and PCT (r = −0.073, p = 0.472).Discussion
In this study, we showed that elderly AECOPD patients
in the ICU had severe disease and high mortality, and
RBP4 levels were lower in non-survivors than survivors.
Lower RBP4 levels were accompanied by a higher mortality.
For the subgroups, RBP4 serum levels were lower in
patients with sepsis than in those without sepsis. RBP4
was an independent predictor of mortality of AECOPD
in elderly patients in the ICU.
RBP4, the circulating transporter for vitamin A, is synthe-
sized in the liver and adipose tissue. RBP4 levels in patients
with AECOPD were significantly lower than those in stable
COPD and healthy subjects, as anticipated from previous
studies using the same assay [24]. RBP4 is elevated in
T2DM and is linked to insulin resistance [12,14,22].Correlation between RBP4 levels and age (r = −0.002, p = 0.988). (b)
11). (c) Correlation between RBP4 levels and sCr (r = 0.224, p = 0.005).
rrelation between RBP4 levels and ALB (r = 0.199, p = 0.057). (f)
ion between RBP4 levels and CRP (r = −0.183, p = 0.044). (h)
Table 3 Prediction of mortality of AECOPD by univariate and multivariate logistic regression analyses
Predictor Univariate Multivariate
OR 95% CI p value OR 95% CI p value
Sex 1.260 0.846–1.505 0.718 1.017 0.822–1.627 0.973
Age 1.099 0.979–1.235 0.110 1.028 0.836–1.412 0.209
BMI 1.355 0.776–1.634 0.247 1.177 0.735–1.709 0.466
APACHE II 2.112 1.872–3.991 0.009 1.978 1.607–4.212 0.023
SAPSII score 2.371 1.846–4.957 0.004 2.043 1.582–5.213 0.012
Glucose levels 1.367 0.942–1.832 0.251 1.209 0.841–2.034 0.418
Albumin 0.957 0.791–1.248 0.076 0.855 0.722–1.377 0.107
White blood cells 1.977 0.953–2.110 0.954 1.843 0.921–2.232 1.021
Total bilirubin 1.173 1.021–4.336 0.032 1.076 1.009–4.455 0.048
BNP 1.721 0.996–3.018 0.056 1.237 0.811–3.247 0.081
Lactic acid 1.315 1.223–7.753 0.022 1.202 1.176–7.802 0.041
CRP 1.413 0.993–3.034 0.189 1.244 0.928–3.149 0.224
Procalcitonin 1.759 0.964–3.021 0.051 1.611 0.872–3.178 0.084
RBP4 0.992 0.895–0.995 0.001 0.926 0.867–0.997 0.007
BMI, body mass index; APACHE, acute physiology and chronic health evaluation; SAPS, simplified acute physiology score; BNP, B-type natriuretic peptide; CRP,
C-reactive protein; RBP4, retinol binding protein-4; CI, confidence interval.
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between patients with and those without preexisting
T2DM on admission to the ICU. This may have been
affected by therapy (for example, insulin, glucose and
catecholamine infusions). In addition, AECOPD patients
reach an advanced state of inflammation where RBP4 is
negligible in insulin resistance [25].
Serum RBP4 levels were associated with nutritional
status in COPD patients. Nutritional status is related to
respiratory impairment and systemic inflammation in
patients with AECOPD [19]. Malnutrition increases the
incidence of complications and mortality, and can beTable 4 Receiver operating curves for the prediction of
mortality (n = 64) in all 100 AECOPD patients on
admission
Parameter AUC (95% CI) p value
RBP4 0.88(0.78-0.94) 0.008
White blood cells 0.59(0.54-0.72) 0.069
C-reactive protein 0.62(0.58-0.77) 0.372
Total bilirubin 0.69(0.61-0.79) 0.057
BNP 0.66(0.52-0.81) 0.083
Lactic acid 0.73(0.51-0.83) 0.054
Procalcitonin 0.71(0.52-0.82) 0.096
APACHE II 0.75(0.66-0.84) 0.036
Combined model (APACHE II/RBP4) 0.78(0.71-0.88) 0.042
SAPS II 0.77(0.67-0.86) 0.028
Combined model (SAPS II/ RBP4) 0.81(0.71-0.91) 0.033
BNP, B-type natriuretic peptide; APACHE, acute physiology and chronic health
evaluation; SAPS, simplified acute physiology score; AUC, area under the ROC
curve; CI, confidence interval.identified as a risk factor associated with short-term
mortality of elderly patients admitted for AECOPD [20].
Low BMI has been shown to be an independent predictor
of in-hospital mortality [24]. In AECOPD patients, low
BMI is associated with a higher degree of bronchial
obstruction and pulmonary hyperinflation [17]. AECOPD
patients have a high risk of malnutrition because of limited
caloric intake and increased energy expenditure, and
the use of mechanical ventilation altered catabolism
[17]. Our results showed that BMI in AECOPD patients
was significantly lower than that in stable COPD patients.
Serum RBP4 levels were significantly lower in AECOPD
patients with a worse nutritional status, and non-survivors’
daily intake of calories (1100 kcal/d) was significantly lower
than the survivors’ intake (1418 kcal/d). We found that
RBP4 levels were positively associated with BMI. Severe
calorie restriction with weight loss reduces circulating
RBP4 levels, and calorie restriction reduces adipose tissue
messenger ribonucleic acid expression of RBP4 [23].
Reduction of RBP4 could be a protective mechanism to
prevent the organism from developing insulin resistance
in an acute inflammatory state and weight loss [26]. RBP4
expression increases with increasing adipose tissue mass
and dietary intake of nutrients can modulate RBP4
concentrations [27]. There is a causal relation between
serum RBP4 levels and adipose tissue mass [28,29].
RBP4 mRNA and protein expressions are high in over-
weight/obese people [30]. In different conditions, RBP4
genetic variants induce RBP4 expression changes in
mRNA and protein levels [31]. Regulatory single-
nucleotide polymorphism in the RBP4 gene modifies
its expression in adipocytes, and RBP4 levels are
Jin et al. Journal of Inflammation 2013, 10:31 Page 8 of 9
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are associated with BMI [32].
Multivariate logistic regression analysis showed that
RBP4 was an independent predictor of mortality. In the
assessment and management of critically ill patients,
knowledge of prognostic factors is crucial to estimate
the risk for mortality. Receiver operating curves for the
prediction of mortality indicated that RBP4 with an
AUC of 0.88 was higher than those of the clinical
scores (APACHE II and SAPS II scores, AUC: 0.75 and
0.77). Our study shows that measurement of RBP4 levels
has a high prognostic use as an early and independent risk
predictor for potential death to complement and thereby
improve the APACHE II and SAPS II scores. Aged
patients with low serum RBP4 levels caused by AECOPD
might have a poor prognosis.
The possible role of low RBP4 concentrations observed
in the circulation of AECOPD patients is unclear. We
consider that at least five reasons may explain this finding.
The first reason might involve inflammation. RBP4 levels
are reduced with individual stress levels of patients, and
thus mirror the stress associated with the severity and
extent of illness [8]. Tumor necrosis factor-α strongly
down-regulates the production of RBP4 in primary
human adipocytes [33]. Inhibition of gene expression
and production of RBP4 by macrophages has been
documented after exposure to bacterial endotoxins, such
as Escherichia coli lipopolysaccharide [34]. We found that
CRP and RBP4 levels were negatively correlated. A second
reason might be insufficient daily calorie intake. Weight
loss and severe calorie restriction promotes reduction
in adipose tissue and plasma levels of RBP4 [23]. Third,
the liver is the main source of RBP4 in humans, and
the non-survivor group had significantly increased TB
serum concentrations compared with the survivor group.
Consequently, reduced serum RBP4 levels in patients are
closely associated with liver function [35]. Fourth, critically
ill or aged patients are more likely to have vitamin A
deficiency. Patients with inflammatory diseases might
benefit from vitamin A supplementation during inflamma-
tory injury. Retinoic acid plays a protective role against
tumor necrosis factor-α-induced lung injury [36]. Fifth,
theoretically, an increase in RBP4 consumption, or removal
increased by extravasation due to capillary leakage or
increased metabolic clearance [14], may play a role.
Conclusions
Serum RBP4 levels in AECOPD patients are correlated
with liver and kidney functions, nutritional status, and
disease stage, but not serum HOMA-IR, and are an
independent factor of overall survival in elderly AECOPD
patients. In the ICU, AECOPD patients with RBP4
deficiency have a greater risk for short-term hospital
mortality, and require more intensive surveillance. Inaddition, we should pay more attention to the function
of RBP4 as a potential determinant of prognosis.
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